bone marrow mesenchymal stem cell with up-regulation of microrna-206 in the treatment of bronchopulmonary dysplasia in newborn mice

Background: bronchopulmonary dysplasia (bpd) is a chronic lung disease of preterm neonates with a few therapeutic options. our previous studies suggested that bone marrow-derived mesenchymal stem cell (bmsc) therapy is effective in the treatment of bpd inmousemodels. furthermore, microrna-206 (mir-206) suggested having a correlation with bpd by regulating the expression of fibronectin 1 (fn1). objectives: the aim of this study was to characterize the role of bmscs with the up-regulation of mir-206 in the treatment of bpd in newborn mice. methods: the bpd mouse model was induced by 60% oxygen. bmscs transfected with mir-206 or negative control (nc) plasmid were administered on postnatal day 7 (p7) and every following week through an intraperitoneal injection (105 cells/animal) until p35. the mice were weighed and their lungs were weighed and prepared for histology. the expression levels of mir-206, fn1, and pulmonary surfactant-associated protein-c (sp-c) were determined through the quantitative polymerase chain reaction and under the immunofluorescence. the protein expression levels of transforming growth factor-β1 (tgf-β1) and interleukin-6 (il-6) were determined by elisa. results: bmscs with up-regulation of mir-206 reduced the degrees of pulmonary edema, improved pulmonary architecture, and attenuated inflammation in bpd mice compared to the nc plasmid group. furthermore, the up-regulation of mir-206 in bmscs down-regulated the expression levels of tgf-β and il-6 in plasma samples and of sp-c and fn1 in the lung tissue of bpd mice. conclusions: bmscswith up-regulation of mir-206 are effective in the treatment of bpdinnewbornmice, and the study introduced a novel idea for the treatment of bpd.